A Phase I Safety and Pharmacodynamic Study of Intravenous Infusion of PLX-PAD Cells in Patients With PAH

Trial Profile

A Phase I Safety and Pharmacodynamic Study of Intravenous Infusion of PLX-PAD Cells in Patients With PAH

Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs PLX PAD (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Sponsors United Therapeutics Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Feb 2016 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 08 Dec 2015 According to a Pluristem Therapeutics Inc. media release, the company announced positive data from 1 cohort of PLX-PAD used for the treatment of Pulmonary Arterial Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top